Lv4
600 积分 2025-01-15 加入
Novel GLP-1-based Medications for Type 2 Diabetes and Obesity
3天前
已完结
Amycretin in obesity: Mechanisms, clinical efficacy, and future perspectives
11天前
已完结
Amycretin, a novel, unimolecular GLP-1 and amylin receptor agonist administered subcutaneously: results from a phase 1b/2a randomised controlled study
11天前
已完结
Safety, tolerability, pharmacokinetics, and pharmacodynamics of the first-in-class GLP-1 and amylin receptor agonist, amycretin: a first-in-human, phase 1, double-blind, randomised, placebo-controlled trial
11天前
已完结
The Dual Amylin and Calcitonin Receptor Agonist KBP-088 Induces Weight Loss and Improves Insulin Sensitivity Superior to Chronic Amylin Therapy
13天前
已完结
A structural basis for amylin receptor phenotype
13天前
已完结
Structural insight into selectivity of amylin and calcitonin receptor agonists
13天前
已完结
Amylin: emergent therapeutic opportunities in overweight, obesity and diabetes mellitus
13天前
已完结
These brain cells clear proteins that contribute to Alzheimer’s
17天前
已关闭
Effects of a Novel Dual Phosphodiesterase 3 and 4 Inhibitor TQC3721 in Patients with COPD in China (PACER-II): a phase 2, multicentre, randomised, double-blind, placebo-controlled trial
24天前
已完结
皖公网安备34019202002308